Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 2
2005 6
2006 5
2007 6
2008 5
2009 2
2012 1
2013 3
2015 2
2017 1
2018 4
2019 1
2020 1
2021 5
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Girndt M, Houser P, Manllo-Karim R, Ervin JE, Charytan C, Chow S, Symonian-Silver M, Lehrner L, Linfert D, Shemin D, Michelsen A, Xie F, Janssen RS. Girndt M, et al. Among authors: janssen rs. Vaccine. 2023 May 11;41(20):3224-3232. doi: 10.1016/j.vaccine.2023.04.028. Epub 2023 Apr 19. Vaccine. 2023. PMID: 37085451 Free article. Clinical Trial.
Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
Girndt M, Plüer M, Dellanna F, Michelsen AK, Beige J, Toussaint K, Wehweck HJ, Koch M, Hafezi Rachti S, Faust J, Bosselmann HP, Witzke O, Janssen RS; HBV-18 Study Investigators. Girndt M, et al. Among authors: janssen rs. Hum Vaccin Immunother. 2022 Nov 30;18(6):2136912. doi: 10.1080/21645515.2022.2136912. Epub 2022 Oct 21. Hum Vaccin Immunother. 2022. PMID: 36269938 Free PMC article. Clinical Trial.
HIV incidence in the United States, 1978-1999.
Vu MQ, Steketee RW, Valleroy L, Weinstock H, Karon J, Janssen R. Vu MQ, et al. Among authors: janssen r. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):188-201. doi: 10.1097/00126334-200210010-00010. J Acquir Immune Defic Syndr. 2002. PMID: 12394798 Review.
Implementing HIV screening.
Janssen RS. Janssen RS. Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S226-31. doi: 10.1086/522542. Clin Infect Dis. 2007. PMID: 18190291
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, Estigarribia G, Sanabria G, Lin MY, Antonio Estrada J, Estephan L, Cheng HY, Chen C, Janssen R, Lien CE. Torales J, et al. Among authors: janssen r. Vaccine. 2023 Jan 4;41(1):109-118. doi: 10.1016/j.vaccine.2022.10.030. Epub 2022 Nov 18. Vaccine. 2023. PMID: 36404171 Free PMC article. Clinical Trial.
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. Cohen EEW, et al. Among authors: janssen r. Clin Cancer Res. 2022 Mar 15;28(6):1157-1166. doi: 10.1158/1078-0432.CCR-21-1411. Clin Cancer Res. 2022. PMID: 34965944 Free PMC article. Clinical Trial.
60 results